|
|
Article: Treatment With INSPRA(TM) Resulted in Significantly Fewer Deaths in Patients Who Have Suffered a Heart Attack Complicated by Heart Failure; EPHESUS Results Simultaneously Presented as a Late Breaker at ACC and Published in NEJM.
- Article from:
- PR Newswire
- Article date:
- March 31, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CHICAGO -- CHICAGO, March 31 /PRNewswire/ -- People who have had a heart attack and also have early complications of heart failure are more likely to survive if they take a new therapy, INSPRA(TM) (eplerenone tablets), plus current standard therapy. These are the findings of the large-scale Eplerenone Post- AMI Heart Failure Efficacy and SUrvival Study (EPHESUS), which found a statistically significant 15 percent relative reduction in all cause mortality and 13 percent relative reduction in a combined endpoint of cardiovascular death and hospitalizations among patients treated with INSPRA compared with patients on current standard therapy. The conclusions of the study ...